A proteomic approach identified growth hormone-dependent nutrition markers in children with idiopathic short stature

Table 1 Auxological data for the children included in the analysis, from whom high-quality spectra were available both before and after 1 year of GH treatment.

	High-responder group				Low-responder group
Variables	Median	Min	Max	N	Median	Min	Max	N
At birth
Gestational age (weeks)	39	38	42	13	39	37	471	19
Height SDS	--1.49	--3.94	1.34	13	--1.93	--3.82	--0.18	19
Weight SDS	--1.90	--2.77	1.59	13	--1.20	--2.89	0.80	19
Pretreatment
Delta height SDS during pretreatment yr	--2.84	--3.57	--2.24	11	--2.88	--4.13	--2.17	18
At GH start
Gender (min = girls, max = boys)		2	11	13		4	15	19
AGA/SGA (min = AGA, max = SGA)		8	5	13		10	9	19
*Age (yrs)	5.84	3.90	10.53	13	9.31	3.32	11.96	19
Height SDS	--2.66	--3.84	--2.04	13	--2.84	--4.33	--1.59	19
Weight SDS	--2.51	--3.56	--1.72	13	--2.20	--4.11	--1.15	19
Father height SDS	--0.98	--1.59	2.12	13	--0.98	--2.95	0.85	19
Mother height SDS	--0.80	--2.04	1.15	13	--1.58	--2.93	0.56	19
MPHSDS	--0.54	--1.81	0.55	13	--1.21	--2.46	0.63	19
GH_max AITT	21.86	20.20	48.07	13	28.75	18.20	63.86	17
*GH_max 24 h	23.81	23.40	39.68	6	53.71	27.12	87.78	12
Diff MPH SDS	--2.13	--3.73	--0.85	13	--1.67	--2.81	--0.34	19
IGF-I SDS	--1.02	--2.56	1.34	11	--0.98	--4.62	1.08	17
*Leptin (ng/mL)	3.96	2.14	5.93	12	2.40	1.21	4.30	17
During treatment
*GH dose (U/kg/day)	0.11	0.09	0.12	13	0.10	0.09	0.11	19
*Change in height SDS 1st yr	0.96	0.89	1.26	13	0.42	0.25	0.51	19

AITT, arginine – insulin tolerance test; GH_max, maximum peak of GH secretion; IGF-I, insulin-like growth factor I; AGA, appropriate for gestational age; SGA, small for gestational age; MPH midparental height; diffMPHSDS, difference in height SDS of the child versus its midparental height SDS
0.1 U GH/kg/day = 33 μg/kg/day
The references used for SDS calculations are [8] for height and weigh and [9] for IGF-I.
* indicates p < 0.05 between groups.

ISSN: 1477-5956